Investment Highlights:- Golden Leaf International is an established E&M (Electrical and Mechanical) engineering contractor with almost 20 years of extensive industry experience, specializing in supply, installation and maintenance of HVAC systems which contributes to over 90% of the Group’s revenue.- For each of the past two financial years, the Group completed over 1,000 projects at different scales. As at 31 July 2025, the Group had 187 projects on hand with backlog value of approximately HK$62.8 million. In addition, the Group has renewed a project for a term of three years commencing from September 2025 with a contract sum expected to be no less than HK$50 million.- For the year ended 31 March 2025, the Group’s revenue increased by approximately 25.6% year-on-year to approximately HK$154.5 million, and the Group’s profit for the year increased by approximately 35.7% to approximately HK$14.1 million. For the year ended 31 March 2025, the Group’s gross profit margin and net profit margin were approximately 20.4% and 9.1%, respectively.- The Group has established business relationships as a main contractor with a wide range of sizeable property managers, reinforcing its solid market position.- The management team has extensive experience in the E&M engineering industry, with Executive Directors boasting over 20-30 years of industry experience.- The Group has developed a cloud-based and customized system “GL ERP” to facilitate efficient project management.- The Group has implemented strict operation systems complying with international standards and certified with ISO 9001:2015 (Quality Management), ISO 14001:2015 (Environmental Management) and ISO 45001:2018 (Occupational Health and Safety Management).HONG KONG, Sep 30, 2025 - (ACN Newswire via SeaPRwire.com) – Golden Leaf International Group Limited ("Golden Leaf International" or the "Company", together with its subsidiaries, the “Group”), a well-established electrical and mechanical ("E&M") engineering contractor in Hong Kong, today announced its listing plan on GEM of Hong Kong Stock Exchange.Before exercising the Offer Size Adjustment Option, the Company plans to offer 100,000,000 shares, with 90% allocated to the Placing and 10% to the Public Offer, at the Offer Price ranging from HK$0.45 to HK$0.65 per Offer Share, which is expected to raise a fund of approximately HK$45 million to HK$65 million.The Public Offer is expected to commence on 30 September 2025 and close at 12:00 noon on 6 October 2025. The allocation results are expected to be announced on or before 9 October 2025. Trading of the Company's shares on GEM is expected to commence on 10 October 2025 under the stock code 8549, with a board lot size of 5,000 shares.Alliance Capital Partners Limited is the Sole Sponsor for the listing. Alliance Capital Partners Limited and CMBC Securities Company Limited are the Joint Overall Coordinators. Alliance Capital Partners Limited, CMBC Securities Company Limited, China Industrial Securities International Capital Limited, First Shanghai Securities Limited, Patrons Securities Limited, Phillip Securities (Hong Kong) Limited, South China Securities Limited, SPDB International Capital Limited and uSmart Securities Limited are Joint Bookrunners and Joint Lead Managers.Golden Leaf International is an established E&M engineering contractor in Hong Kong with almost 20 years of industry experience, specialising in HVAC systems works, which accounted for over 90% of the Group’s revenue. The Group also undertakes electrical systems works, and plumbing and drainage systems works.For each of FY2023/24 and FY2024/25, the Group completed over 1,000 projects at different scales. For the year ended 31 March 2025, the Group’s revenue increased by approximately 25.6% to approximately HK$154.5 million, and profit for the year increased by approximately 35.7% to approximately HK$14.1 million, compared to the previous financial year. The gross profit margin and net profit margin were 20.4% and 9.1%, respectively, for FY2024/25. As at 31 July 2025, the Group had 187 projects on hand with a backlog value of approximately HK$62.8 million. In addition, the Group has renewed a project for a term of three years commencing from September 2025 with a contract sum expected to be no less than HK$50 million.The Group has maintained many years of business relationships with sizable property managers in Hong Kong. Revenue from the top five customers accounted for approximately 64.5% and 68.1% of the Group’s total revenue for the years ended 31 March 2024 and 2025, respectively.The Group’s project portfolio covers commercial properties across Hong Kong Island, Kowloon and the New Territories, including Olympian City in Tai Kok Tsui, China Hong Kong City in Tsim Sha Tsui, Citywalk in Tsuen Wan, Hang Lung Centre in Causeway Bay, Fashion Walk in Causeway Bay, Peak Galleria at the Peak, AIA Tower in North Point, Metro Harbour Plaza in Tai Kok Tsui, The Center in Central, Taikoo Place in Quarry Bay, AIRSIDE in Kai Tak and the Metropolis Tower in Hung Hom.The Company’s management team is experienced and up-to-date with the development of the E&M engineering industry. Mr. Ip Kam Yik, the Chairman of the Board, Chief Executive Officer, Executive Director and one of the founders of the Company, has over 20 years of experience in the E&M engineering industry. Mr. Lui Kwok Kit, Executive Director and one of the founders of the Company, has over 30 years of experience in the E&M engineering industry with extensive on-the-ground experience.The Group has developed a cloud-based "GL ERP" system to facilitate efficient project management, covering tender preparation and approval, project progress monitoring and financial management. Moreover, the Company has implemented strict operation systems complying with international standards and fully certified with ISO 9001:2015 (Quality Management), ISO 14001:2015 (Environmental Management) and ISO 45001:2018 (Occupational Health and Safety Management).The market size for HVAC works in Hong Kong has shown robust growth, driven by urban renewal, sustainability initiatives, and technological advancements. The private sector has been the dominant driver of this growth, expected to grow at a CAGR of approximately 5.8% from 2025 to 2029 reaching approximately HK$8,318.3 million by 2029, reflecting steady demand for upgrades and smart HVAC technologies.The Company intends to use the net proceeds from the Share Offer as follows: approximately 56.1% to finance up-front costs for new projects; approximately 32.6% for recruiting new staff and leasing an additional office; approximately 1.3% for upgrading the "GL ERP" system; and approximately 10% for general working capital purposes.Media Enquiries:Strategic Financial Relations (China) LimitedMs. Anita CHEUNG Tel: (852) 2864 4827Ms. Coco ZHANG Tel: (852) 2864 4830Ms. Alison YIU Tel: (852) 2864 4897Email: sprg-goldenleaf@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 29, 2025 - (ACN Newswire via SeaPRwire.com) – Bamboos Health Care Holdings Limited ("Bamboos" or the "Group", Stock Code: 2293) announced its annual results for the year ended 30 June 2025 (the "Period" or the "Year") on September 30th. The Group's overall business remained stable during the year, continuing its consistent focus on shareholder returns, and declared a final dividend for 2025 of HK1.50 cents per ordinary share.During the Period, the Group's revenue was approximately HK$74.4 million. The revenue from the provision of healthcare staffing solution services was approximately HK$61.7 million, comprising approximately HK$35.2 million from institutional staffing solution services and approximately HK$26.5 million from private nursing staffing services. Other income increased year-on-year to HK$1.6 million. Profit before income tax was approximately HK$22.4 million. Profit attributable to equity holders of the Company for the year amounted to approximately HK$17.5 million. Finance income increased year-on-year to approximately HK$1.6 million for the year. Total assets remained stable, with current assets maintaining a healthy level.Furthermore, during the year, the Group also utilized idle cash balances to acquire SPDR Gold Trust, which is a standalone investment trust and an exchange trade fund which holds gold bullion (the "Acquisitions"), enhancing the efficiency of utilizing the Group's idle cash. The Board considers that the Acquisitions provide the Group with opportunity to balance and diversify its investment portfolio, as well as protecting the Group from currency debasements and inflation in times of uncertainty.As of 30 June 2025, the number of healthcare personnel registered with the Group increased by 7.4% year-on-year to approximately 32,000, from 29,800 in the same period last year. This steadily growing, large, and diverse pool of registered healthcare personnel not only demonstrates the Group's favorable benefits and talent retention rate but will also help the Group further enhance its competitive strength and seize business development opportunities.Actively Advances Integration of 'Technology+Innovation' with Healthcare, New 'Bamboos Health' Ecosystem Holds Broad Development SpaceWith healthcare staffing solutions at its core, Bamboos provides professional, comprehensive, reliable, and customized institutional support services and home care nursing solutions for the Hospital Authority, private hospitals, social welfare organizations, clinics, and research medical institutions. While steadfastly maintaining its core business in recent years, the Group has actively promoted the integration of "Technology + Innovation" with healthcare, continuously optimizing service quality and efficiency, deepening business cooperation, and expanding business scope. By integrating three major service sectors – Preventive Medicine, Chinese and Western Medical Services, and Smart Elderly Care and Age-Friendly Living Solutions – the Group has built a new "Bamboos Health" ecosystem.During the year, the Group also actively utilized its self-owned physical space in Mong Kok, and has established a service platform integrating healthcare, smart home AI elderly care technology, and data – "healtHUB". It has evolved from initially providing healthcare staffing solutions into a health technology ecosystem platform covering the full lifecycle of "Prevention-Treatment-Rehabilitation-Home Care-Smart Elderly Care", providing a one-stop healthcare and smart home service solution empowered by "Technology + Innovation".Given the ongoing trends of population ageing and healthcare manpower shortages, coupled with the broad prospects of the global AI healthcare market, Bamboos' focus on "Technology + Innovation" empowerment and its business coverage of the full lifecycle aligns with healthcare industry development trends. Simultaneously, the Group actively responds to national and government policies, echoing China's "Healthy China 2030" Plan Outline and supporting the development of Hong Kong's Primary Healthcare system. This not only allows multiple business lines to benefit from long-term policy support and access stable government business resources but also creates synergies with other operations, presenting Bamboos Health Care with extensive, stable business demand and medium-to-long-term sustainable growth potential.Ms. Hai Hiu Chu, Chairman and Chief Executive Officer of Bamboos Group, said, "Bamboos will continue to dedicate itself to strengthening and consolidating its core business and becoming a more renowned market leader, while actively seeking new business opportunities, advancing the integration of 'Technology + Innovation' with healthcare, and forming alliances or partnerships with strategic collaborators to pursue greater diversification of the Group's business, supporting Bamboos' sustainable growth and the strategy of maximizing shareholder returns."About Bamboos Health Care Holdings LimitedBamboos Health Care Holdings Limited provides a one-stop healthcare and smart home service solution empowered by "Technology + Innovation". Since its establishment in 2009, the Group has always adhered to the service philosophy of "Care • Competence • Commitment". In recent years, while steadfastly maintaining its core business, the Group has promoted the integration of "Technology + Innovation" with healthcare, continuously optimizing service quality and efficiency, deepening business cooperation, and expanding business scope. By integrating three major service sectors – Preventive Medicine, Chinese and Western Medical Services, and Smart Elderly Care and Age-Friendly Living Solutions – the Group has built a new "Bamboos Health" ecosystem. The Group also actively utilized its self-owned physical space in Mong Kok, establishing a service platform integrating healthcare, smart home AI elderly care technology, and data – " healtHUB". The Group has now evolved from initially providing healthcare staffing solutions into a health technology ecosystem platform covering the full lifecycle of "Prevention-Treatment-Rehabilitation-Home Care-Smart Elderly Care".With healthcare staffing solutions at its core, Bamboos boasts a network of over 32,000 qualified professional healthcare personnel, providing professional, comprehensive, reliable, and customized institutional support services and home care nursing solutions for the Hospital Authority, private hospitals, social welfare organizations, clinics, and research medical institutions. To date, the Group has served over 3,500 nursing homes / rehabilitation centres / clinics. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

DUBAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - 31 CONCEPT (31C), a leading UAE-based cybersecurity innovator, today announced the strategic acquisition of Xynthor AI Software Inc., a Canadian company pioneering AI-native Data Loss Prevention (DLP) solutions. This acquisition strengthens 31C's commitment to advancing Deep Packet Intelligence (DPI), corporate security, and data sovereignty in an AI-centric world.31 Concept & XynthorBy integrating Xynthor's "DLP for AI Era" with 31C's DPI expertise, the combined platform will deliver the most comprehensive AI-aware security solution available. This move addresses the growing need for security systems capable of handling modern AI-driven workflows.Why It MattersThe rise of generative AI tools such as ChatGPT and Claude has outpaced the capabilities of traditional DLP systems, which were built for structured data and static rules. High-profile incidents, including the accidental leakage of proprietary source code by Samsung engineers using ChatGPT, highlight the urgent need for AI-specific safeguards.Misha Hanin, CEO of 31C, emphasized: "The convergence of AI and cybersecurity is the most significant paradigm shift our industry has ever seen. Traditional methods cannot manage the dynamic, context-aware data flows of today's AI environments. Through this acquisition, we are pioneering an entirely new category of AI-native security solutions."Xynthor's Breakthrough TechnologyXynthor brings several unique differentiators:AI Data Guardian: Prevents sensitive information from leaving the organization using NLP-driven detection.Air-Gapped Architecture: Keeps analysis inside the client's environment, ensuring privacy and compliance.Context-Aware Intelligence: Reduces false positives through AI-driven classification and behavioral analysis.Private LLM Protection: Enables safe use of internal large language models without external exposure.Seamless Integration: Works with existing infrastructure while supporting regulations like HIPAA and GDPR.Comprehensive AI-Era PlatformThe integrated platform enhances DPI with real-time policy management, adaptive threat detection, and behavioral analytics. It also streamlines compliance with GDPR, HIPAA, PCI DSS, and upcoming AI governance standards.Boris Heismann, CTO of 31C, stated: "We're not only responding to current demands but anticipating tomorrow's challenges. Combining DPI with AI-native DLP creates a future-ready security platform."Strategic ImpactThe global cost of data breaches averages over $4 million per incident, and AI-driven risks are only increasing. By uniting DPI and AI-native DLP, 31C positions itself as a global leader capable of addressing these critical challenges.This acquisition aligns with 31C's growth strategy, including performance-based incentives tied to Xynthor's product success. Both companies will continue to operate from the UAE and Canada, combining their strengths to accelerate innovation and market expansion.About 31CFounded in the UAE, 31C is a cybersecurity company specializing in Deep Packet Intelligence, corporate security, and data sovereignty. Its innovative approach makes it a trusted partner for enterprises, governments, and regulators worldwide.About Xynthor AIBased in Canada, Xynthor AI develops AI-native security platforms designed to protect organizations using generative AI, ensuring both safety and compliance in the AI era.For more information about 31C's Next Gen DPI solutions, visit https://31c.io.Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 Concept Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 29, 2025 - 28 September, The world's first 9,300 CEU methanol dual-fuel Pure Car and Truck Carrier (PCTC), "CM HONG KONG", celebrated its maiden voyage with a ceremony in Tsing Yi, Hong Kong. Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, Deputy Director of the Liaison Office of the Central People's Government in the HKSAR, Qi Bin, and Chairman of China Merchants Group Limited, Miao Jianmin, etc. attended the ceremony, with Executive Vice President of China Merchants Group Limited, Deng Renjie, as the master of ceremonies.During the event, a commemorative plaque was presented to the ship's captain. Guests toured the vessel's bridge, crew quarters, and innovative methanol dual-fuel system, witnessing its advancements in low-carbon technology and operational efficiency.Built for China Merchants Energy Shipping (CMES), "CM HONG KONG" is the first large-scale car carrier powered by a methanol dual-fuel system, enabling seamless switching between conventional fuel and methanol. Compliant with IMO Tier III emission standards, it achieves over 70% emissions reduction when using green methanol. The ship, measuring 219.9 meters long and 37.7 meters wide, has a design capacity of 9,300 CEUs, with an actual capacity of up to 9,492 CEUs. Its 78,416-square-meter loading area, equivalent to 11 football fields, features 13 decks, including three adjustable lift decks and three tailored for hydrogen fuel cell vehicles. Dual stern and side ramps boost loading/unloading efficiency by 30%. Safety is enhanced with 156 CCTV cameras and thermal imaging infrared sensors across all decks."CM HONG KONG" embarked on its inaugural China-to-Europe route, unloading vehicles in Hong Kong before heading to Europe. Leveraging Hong Kong's free port status, CMES aims to advance the "green fuel trade + port services" model, fostering economic growth, attracting international vessels for green fuel bunkering, and strengthening Hong Kong's role as a global green maritime hub.Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, delivered a speech at the ceremony.Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, delivered a speech at the ceremony.Chairman of China Merchants Group Limited, Miao Jianmin, delivered a speech at the ceremony. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - The future arrived today in Singapore as the World Quantum Summit 2025 (WQS) — themed “Quantum Unboxed: Extending the Reach of AI” — concluded at the Sheraton Towers Singapore with a full house attendance filling the ballroom to capacity. The overwhelming turnoutunderscored the growing global appetite for practical quantum solutions that extend the power of artificial intelligence and accelerate its real-world impact.This year’s summit was not a standalone event but the culmination of a three-day intensive journey into the future of computing and intelligence. On 23–24 September, participants took part in a sold-out Executive Workshop on Quantum and AI, which built foundational understanding of quantum principles, emerging architectures, and integration strategies. The final day brought it all together, showcasing how those concepts are now being deployed in industry — from real-world applications to large-scale investment strategies.Unlike traditional conferences focused solely on research or theory, WQS 2025 brought together the entire ecosystem driving quantum innovation forward. The summit featured practitioners representing different quantum approaches, policy makers, venture investors, academics, corporates, researchers, and ecosystem partners — all converging under one roof to chart the path from lab breakthroughs to industry-scale adoption. On the exhibition floor, leading players such as ST Engineering, QBoson, and TM Research & Development showcased quantum - enhanced solutions in optimisation, secure computing, and AI acceleration. Meanwhile, Gold Capital Network Partners — IMGT and IWC Management — hosted curated sessions connecting founders and investors to accelerate funding into quantum ventures poised for growth.A key highlight was the line-up of 19 world-class speakers, each offering cutting-edge insights into how quantum is transforming the AI landscape. Among them were Assoc. Prof. Mile Gu, Deputy Director of the Nanyang Quantum Hub at Nanyang Technological University; Jeremy Woo, Senior Technical Advisor at D-Wave System; Deepak Waghmare, CTO (APJC) of Dell Technologies; Ujjwal Kumar, Principal Architect, Office of the CTO at Microsoft Asia; Dr. Simon See, Senior Director and Global Head of the NVIDIA AI Technology Center; Bruno Aznar Martinez, R&D Software Developer at Keysight Technologies; Raghunath Koduvayur, CEO of RAQS Quantum; Gao Qi, Algorithm Director at QBoson; Ken Chew, CEO and Partner of IWC Management; and Tony Gu, General Partner at NGC Ventures. They were joined by Ong Yongcheng of Insignia Ventures, Dr. Amelia Tan of ST Engineering, Eric Lee of Deloitte Southeast Asia, Atsushi Sugiura of Oxford Quantum Circuits, Hidetoshi Matsumura of Fujitsu Limited, Ray Han of SAP, Duleesha Kulasooriya of Deloitte, Manisha Sharma Kohli of Google, and Simon Lawrie of AWS.Throughout the summit, a clear narrative emerged: quantum computing has moved beyond theory into strategic deployment, offering a powerful multiplier for AI. Industry leaders showcased case studies where quantum-enhanced AI is already delivering breakthrough results — from accelerating molecular simulations and optimising financial portfolios to solving supply chainchallenges previously considered intractable. Discussions highlighted how enterprises are integrating quantum capabilities directly into their AI workflows, achieving dramatic improvements in processing power, speed, efficiency, and cost-to-insight.The summit also reflected the shifting investment landscape. As quantum technologies mature, institutional and venture capital investors are moving rapidly to back companies with commercially viable products and near-term revenue potential. “Quantum is no longer the future — it’s today’s most powerful strategic edge and already seeing some real applications,” said Ken Chew, CEO of IWC Management. “The confluence of quantum and AI and their cross-synergies are powerful and those who integrate it into their AI stack early will potentially define the competitive landscape of the next decade.”By the close of the event, one message was clear: quantum will not replace AI — it will supercharge it. With practitioners, investors, policymakers, and researchers now aligned on the urgency of adoption, the era of practical quantum applications is no longer a distant vision — it is here, and it is redefining howindustries think about computation, intelligence, and innovation.The World Quantum Summit has firmly established itself as Asia’s premier platform for quantum commercialisation, bridging science, industry, and capital to accelerate real-world adoption. With its unique focus on applications over abstraction and its ability to convene the full quantum ecosystem, WQS is not just a conference — it is a catalyst for the next wave of technological transformation.Media Contact:Eric KhooConference Director, TPGI Pte Ltderic.khoo@pinnaclegroup.global+65 8383 2480 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA).Builds on China approval and strong Phase III and real-world clinical results showing durable glucose control and safety.Positions Hong Kong as a strategic gateway for Hua Medicine’s global expansion into Southeast Asia and beyond.SHANGHAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world’s first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D).The acceptance of the NDA marks an important milestone in Hua Medicine’s strategy to expand beyond China, bringing its innovative, disease-modifying treatment to more patients across Asia and ultimately to global markets.With more than half a million people living with diabetes in Hong Kong and nearly 240 million across Asia, the NDA represents a significant step toward addressing one of the region’s most urgent health challenges.A first-in-class therapy with global potentialDorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients, 1) It can be used as mono-treatment for drug-naïve T2D patients, as first-line treatment, 2) When metformin hydrochloride alone has poor blood glucose control, it can be used in combination with metformin hydrochloride. Unlike conventional drugs that manage symptoms, dorzagliatin targets the root cause of blood sugar dysregulation by repairing the function of glucokinase (GK), the body’s glucose sensor. By restoring glucose sensitivity, dorzagliatin helps maintain blood sugar balance and supports long-term disease management.Results from two Phase III registration trials in China demonstrated that dorzagliatin significantly and sustainably lowered HbA1c levels, improved pancreatic β-cell function, and reduced insulin resistance, all while showing strong safety and tolerability. Findings are being further validated in ongoing real-world studies, of which some interim analysis and data were presented at the 2025 American Diabetes Association (ADA) Scientific Sessions.Strategic gateway to new marketsHong Kong has established a comprehensive, community-based system for diabetes management and serves as a medical and financial hub for the region. Research findings from the Hong Kong Diabetes and Obesity Research Institute at The Chinese University of Hong Kong indicate that the implementation of a community-based public-private collaboration model for diabetes management provided significant benefits to the community. The advanced experience in Hong Kong is of great significance for improving the quality of life of diabetes patients, controlling the progression of the disease, and reducing the burden on the healthcare system. Once approved in Hong Kong, it will also provide clinical application of dorzagliation for the personalized management of diabetes.According to Hong Kong's former new drug approval mechanism, applicants were required to submit to the authority new drug registration certificates issued by the drug regulatory agencies of two or more recognized countries, as well as other specified relevant documents, in order to support the approval and marketing of the product. Under the newly established "1+" mechanism, after meeting requirements such as local clinical data support and having the applicable scope of the new drug endorsed by local experts, an applicant only needs to submit the approval from one (instead of the original two) reference drug regulatory authority to apply for registration of the new drug in Hong Kong. This mechanism initially applied to new drugs for the treatment of serious or rare diseases, and has been extended to all new drugs since 2024.Under the leadership of Ms. Beili Cao, Vice President of Department of Corporate Operation and Great Bay Development, Hua Medicine has conducted sufficient and in-depth communications with local clinical experts and regulatory authorities in Hong Kong, and became an early pioneer of this mechanism. The Company filed its application for registration of dorzagliatin in Hong Kong at the end of July, and the application was officially accepted by the end of September.Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine, said: “Acceptance of dorzagliatin’s NDA in Hong Kong is not only recognition of its clinical value but also a pivotal step in Hua Medicine’s international journey. Hong Kong’s unique position as a regional healthcare leader and financial hub makes it the ideal gateway for expanding dorzagliatin’s reach into Southeast Asia and beyond. We are committed to working with local doctors and partners in Hong Kong to explore dorzagliatin’s potential in both treatment and prevention of prediabetes and early-stage diabetes, ensuring more patients worldwide can benefit from this breakthrough therapy.”Dorzagliatin: A transformative T2D treatmentDorzagliatin was approved in September 2022 in China, and it was included in the country’s National Reimbursement Drug List (NRDL) as of January 1, 2024.Dorzagliatin can be used alone as a first-line therapy for newly diagnosed patients, or together with metformin when blood sugar control is inadequate. Unlike many other approved oral antidiabetes drugs, no dose adjustment is required for patients with kidney impairment. It works by repairing the body’s glucose sensor, glucokinase (GK), restoring glucose sensitivity and long-term blood sugar balance. It acts across key organs—stimulating insulin secretion in the pancreas, boosting GLP-1 secretion in the gut, and regulating glycogen in the liver. This multi-target approach addresses the root cause of Type 2 diabetes, not just its symptoms.The NDA application in Hong Kong is based on the results of two Phase III registration clinical studies conducted in China evaluating the use of dorzagliatin monotherapy and in combination with metformin for the treatment of patients with Type 2 diabetes. Two studies have shown that for two categories of T2D patients—those newly diagnosed and not yet on medication, and those who have failed to respond adequately to metformin therapy— dorzagliatin can sustainably and effectively lower patients' HbA1c levels by repairing defects in the glucose sensor function of GK, significantly reduce postprandial two-hour blood glucose levels (2h-PPG), achieve high glycemic control rates without hypoglycemia, demonstrate good safety and tolerability, and continuously improve β-cell function and reduce insulin resistance.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsWebsite: ir@huamedicine.comMediaWebsite: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Sep 29, 2025 - (ACN Newswire via SeaPRwire.com) – Quantum Solutions Co., Ltd. (Tokyo Stock Exchange Code: 2338.T, “Quantum”) announced its strategic financing initiative on September 26 to issue 44 million shares to a blue-chip investor mix of three heavyweight institutions, providing the necessary permanent capital and network access to position Quantum as a potential frontrunner in the world of Ethereum (ETH) listed strategies and a showcase standout in the Tokyo stock market.For Japanese investors, this represents another significant commitment by leading US capital, following Warren Buffett’s investment in Japan’s five major trading companies. For international investors, it signals that Tokyo’s stock market is an increasingly attractive destination for global capital, welcoming new opportunities for “smart money”.Dream Team of Global Capital Aligns for Quantum, International Demand for Japanese Equities Continues to GrowQuantum’s investor line-up is a market stunner in the emerging field of crypto-linked equities. Susquehanna International Group (SIG), investing via CVI Investments, holds the capital firepower to accelerate Quantum’s ETH accumulation and expand its balance sheet for upcoming fundraising rounds. With a portfolio that includes early investments in ByteDance and Strategy Inc. (NASDAQ: MSTR), SIG is a Tokyo Stock Exchange participant, offering the robust capital infrastructure that analysts consider essential for a successful Digital Asset Treasury (DAT).Cathie Wood affirms her position as the world’s leading investor in crypto-linked equities with ARK Invest’s first direct foray into APAC-listed opportunities. In the US market, ARK has a track record for identifying category leaders such as ETH Treasury Bitmine Immersion Technologies (NYSE: BMNR) and cryptocurrency exchange Coinbase (NASDAQ: COIN). By adding Quantum, Wood extends her expertise to the Tokyo market, bringing visibility to Quantum in front of the global investing audience as the region’s most promising ETH Treasury initiative.The third participant is Hong Kong-based Integrated Asset Management (IAM), led by Mr. TC Yam. As the majority shareholder of Forbes Media, IAM’s cross-sector presence in international finance and media resources bolsters Quantum’s capital depth and reputational standing. Like ARK, IAM makes its first public investment in the Tokyo stock market, signaling growing confidence among global institutional investors in Japan's equity market.The fundraise utilizes convertible bonds and both floating and fixed strike price warrants for a total issuance of approximately 44 million shares, nearly doubling the company’s existing share capital. None of the instruments are priced at a discount, a rarity for DAT fundraises, suggesting that the incoming investors are targeting long-term growth prospects. As of market closing on September 26, the nominal value of the financing round comes to over JPY 26 billion (approx. USD 180 million), with the first tranche valued at JPY 22.1 billion (approx. USD 150 million).First ETH Treasury in Japan — A Differentiated Strategy Offering Long-Term Returns on EquityAccording to research reports by leading investment banks, the key determinants of success for listed Digital Asset strategies are robust access to capital and a team with operational blockchain expertise. Through this fundraising initiative, Quantum taps into fresh sources of capital and aligns with investors of strong reputation, prompting market expectations of long-term backing.Quantum CEO Francis B. Zhou is no newcomer to the Digital Asset industry, as one of the first institutional investors and operators in the blockchain space. In 2018, Zhou acquired the world’s second largest ETH mining facility, based in Jokkmokk, Sweden. Zhou maintains investments in early stage blockchain projects alongside film and IP holdings in his venture investment portfolio, and brings a network of experienced blockchain operators, including Head of Crypto Strategy Donny Chi.Proceeds from Quantum’s financing initiative will be used to accumulate ETH. Although BTC has demonstrated adoption as a store-of-value, ETH is the foundational asset for blockchain applications, enabling companies like Quantum to explore attractive yield-generating opportunities to drive a blend of organic and inorganic growth for the company’s core treasury and balance sheet.The appeal of yield-bearing strategies is supported by data from the US market, which indicates that listed ETH Treasuries trade at a price-to-book multiple of 7.72x, more than 3 times higher than that of listed BTC Treasuries. More remarkably, the price-to-book of ETH Treasuries is trending upwards, increasing by over 20% within the trading month of September, demonstrating that the market expectations continue to strengthen for listed ETH Treasuries as it relates to long-term returns on equity.Zhou and the Quantum Solutions team have a history of exploring growth frontiers, consequently developing industry traction in AI computing, GPU hosting, and IP gaming. This positions the company to pursue unique opportunities beyond overcrowded sectors in Real World Asset (RWA) space to potentially generate more attractive returns.With the fundraise, Quantum’s notional price-to-book multiple is estimated to be less than 30% of the market median. Assuming that the company can reach its fair value, the structure of the fundraise allows the company to rapidly accelerate its capital accumulation to reach the target of 100,000 ETH within the near term, positioning Quantum among the leading ETH Treasury companies globally.Growth Driven Policies in Japan Encourage Prospects for Long-Term Shareholder ValueConsistent government support for the blockchain industry and increasing clarity in regulations are ushering in a more investor-friendly market for Digital Assets in Japan. Whereas the US market already has ETH Treasury companies such as Bitmine (NASDAQ: BMNR) and SharpLink Gaming (NASDAQ: SBET) achieving significant market cap growth as capital market highlights, Japan lacks a similar listed benchmark. Quantum Solutions’ entry fills this gap, opening a new chapter as "Japan’s first”, and creating conditions for capital inflow and renewed market participation.This financing round, nominally valued at approximately USD 180 million, is a landmark in both the Japanese stock market as well as the crypto-linked equities space. Through the combined endorsement of SIG, ARK, and IAM, Quantum not only secures funding but also international validation under a capital structure optimized to maximize long-term shareholder value. High-profile deals of this caliber further Tokyo as an emerging destination for savvy investors. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com